Biscor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biscor

Biscor is a specific medicinal name for a prescription-only medication whose active substance is Bisoprolol Fumarate (or its hemifumarate salt), which is a product of pharmaceutical synthesis. It is administered exclusively via oral administration in the dosage form of a film-coated tablet. The drug is classified as a single active ingredient product, focusing solely on the targeted effects of Bisoprolol.


Defining Biscor: Identity and Pharmacological Class

Biscor belongs to the pharmacological class of beta-blockers, specifically identified as a selective beta1-adrenergic receptor antagonist. At typical therapeutic levels, Bisoprolol primarily targets the beta-1 receptors found predominantly in the heart, a feature that distinguishes it from non-selective beta-blockers that influence receptors throughout the body. The drug's identity as a potent compound is well-established in cardiovascular therapeutics.

Composition and Form: The Synthetic Tablet

The medicine is provided in the dosage form of a film-coated tablet, intended exclusively for oral administration. The tablet is composed as a single active ingredient product, containing Bisoprolol hemifumarate combined with solid excipients that are necessary to create the stable matrix structure. This standardized, oral form ensures a reliable and consistent method for introducing the active substance into the systemic circulation.

High-Level Purpose: Moderating the Heart's Activity

The fundamental purpose of Biscor is to aid the heart in performing its function more efficiently by consistently reducing its overall workload. Its mechanism involves reducing the intensity of signals from the sympathetic nervous system, including those triggered by adrenaline, on cardiac tissue. This competitive inhibition results in both a slowing of the heart rate and a reduction in the force of contraction. This action serves to diminish the energetic demands placed upon the cardiovascular system. This therapeutic principle is the foundational basis for its long-term general application.

Regulatory References

  1. Bisoprolol Drug Information

What side effects are possible with Biscor?

Possible side effects and safety information

The safety profile of Biscor (Bisoprolol Fumarate) is documented in regulatory sources through classifications of adverse reactions based on how often they occur and which physiological systems are affected. These classifications are consistent with official regulatory standards, such as those used by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Frequency-Classified Adverse Reactions

Adverse effects are categorized into frequency tiers. Very Common reactions, reported most often in patients being treated for chronic heart failure, include a slowed heart rate (bradycardia). Common reactions (occurring in 1% to 10% of patients) typically involve the nervous system and general systemic effects, such as fatigue, dizziness, and headache. These common symptoms are noted to occur especially at the beginning of therapy and may subside after the initial one to two weeks of treatment. Common gastrointestinal effects include nausea and diarrhoea.

Uncommon reactions (0.1% to 1%) include sleep disorders and depression. Within the cardiovascular system, uncommon effects may include the worsening of pre-existing heart failure and AV-conduction disturbances. Rare effects (less than 0.1%) affect diverse systems, including the eyes (reduced tear flow), and may involve syncope or hallucinations.

Serious Safety Constraints

Regulatory documents emphasize that the use of Biscor is contraindicated in several high-risk conditions, including acute or decompensated heart failure and severe bradycardia. Furthermore, a warning is issued that the abrupt cessation of therapy can lead to an exacerbation of angina pectoris or, in rare cases, myocardial infarction, particularly in patients with coronary heart disease.

Safety notes for specific populations include that Biscor may mask symptoms of hypoglycaemia in diabetic patients. Use during pregnancy and in pediatric populations is not generally recommended due to insufficient data or potential for adverse fetal effects, such as growth retardation.

Overdose and Emergency Response

Overdose and when to seek help

Overdosing on Biscor (Bisoprolol Fumarate) is a serious event that requires immediate emergency medical attention, as documented in regulatory information. The official overdose profile is characterized by profound effects on multiple physiological systems.

Documented Overdose Manifestations

Official labeling describes that an overdose may present with severe cardiovascular depression, including significant bradycardia (abnormally slow heart rate), marked hypotension (abnormally low blood pressure), and Heart Block (a severe conduction delay). Other regulator-listed manifestations include a worsening of congestive heart failure and effects on other systems, such as bronchospasm, hypoglycemia (low blood sugar), and severe Central Nervous System (CNS) effects that can lead to confusion, seizures, or coma.

Mandatory Emergency Actions

Regulators explicitly require patients to seek medical help right away if too much medicine is taken. Immediate contact with emergency services or the Poison Control Helpline is mandated. Urgent medical attention is required if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management described in official prescribing information is primarily symptomatic and supportive, as no specific antidote is known for Bisoprolol overdose. Procedures may include administering intravenous fluids, agents to treat low blood pressure, and specific interventions like IV Atropine for severe bradycardia or IV glucose for hypoglycemia. Official documents note that low blood sugar is common in children following this type of overdose and can lead to nervous system symptoms. Hospital monitoring and required tests, such as an ECG (heart tracing), are often necessary procedures.

Therapeutic Uses of Biscor

What Biscor Treats: Main Uses and Benefits

Biscor (Bisoprolol Fumarate) is generally used for the sustained management of chronic cardiovascular conditions, contributing to managing symptoms that create noticeable physiological strain and supporting general well-being.

This supportive approach is primarily applied in conditions such as essential hypertension (high blood pressure), stable chronic heart failure (specifically HFrEF), and chronic stable angina pectoris (chest pain).

Therapeutic Focus and Relief

In high blood pressure, the primary benefit is sustained pressure control, which is considered relevant for easing the risk of subsequent major cardiovascular events. For stable chronic heart failure, this supportive approach assists with maintaining functional stability and is relevant for easing the symptom burden of shortness of breath and fatigue. For patients managing coronary artery disease, Biscor is commonly used to help address symptom clusters that may become intense or disruptive, such as exertional chest pain.

“This supportive approach helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.”

Quick Fact: Relief for Functional Strain

Biscor is primarily relevant for easing symptoms linked to organ-specific functional stress, such as exertional chest discomfort, or symptoms that interfere with daily functioning like fatigue, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Biscor (Bisoprolol Fumarate) is permitted for use in adults aged 18 and over for its labeled indications. However, governmental regulatory documents specify distinct population groups for whom the medicine is prohibited or restricted.

Contraindicated Populations

Biscor is contraindicated and must not be used in patients with the following conditions, as stated in official labeling:

  • Acute Heart Failure or decompensation requiring intravenous support.
  • Cardiogenic Shock or Symptomatic Hypotension.
  • Second or Third Degree AV Block or Marked Sinus Bradycardia.
  • Severe Bronchial Asthma or Severe Chronic Obstructive Pulmonary Disease (COPD).
  • Metabolic Acidosis or Severe Peripheral Arterial Occlusive Disease.

Eligibility Restrictions and Limitations

Category Official Regulatory Status
Pediatric Use Not recommended; safety and efficacy have not been established in children or adolescents (lt 18 years).
Pregnancy/Lactation Not recommended; potential risks to the fetus or infant are cited in labeling.
Organ Impairment Use requires caution and may necessitate a lower maximum dose in patients with Severe Renal or Severe Hepatic Impairment.
Co-morbidities Conditional use only in patients with less severe bronchospastic diseases or diabetes, due to the risk of masking symptoms like tachycardia.

Connection to the overall eligibility profile: The regulatory profile establishes non-eligibility through a core list of absolute cardiac and pulmonary contraindications. Eligibility for other populations is restricted by official caveats concerning age, reproductive status, and the presence of severe organ dysfunction or specific co-morbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Biscor (Bisoprolol Fumarate) is primarily defined by the potential for pharmacodynamic effects, involving additive actions on heart function and blood pressure, as stated in regulatory documents.

Official Interaction Restrictions

Classification Interacting Substance/Class Official Constraint
Contraindicated Floctafenine, Sultopride Strictly prohibited due to risk of severe cardiovascular complications.
Not Recommended Verapamil, Diltiazem Generally avoided due to heightened risk of profound hypotension and AV block.
Not Recommended Centrally-acting Antihypertensives Avoided due to potential for rebound hypertension upon abrupt withdrawal.

Documented Pharmacological Interactions

Co-administration with Class I Antiarrhythmics (e.g., Disopyramide) or Digitalis Glycosides may potentiate effects on atrioventricular conduction time and heart rate. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may officially reduce the blood pressure-lowering effect of Biscor. The regulatory labeling notes that the antibiotic Rifampin increases the metabolic clearance of Biscor, resulting in a shortened elimination half-life. Regarding non-medicinal substances, the combination with Alcohol (Ethanol) may increase the risk of hypotension and dizziness. Furthermore, caution is noted in patients with Diabetes Mellitus, as Biscor may mask certain signs of hypoglycemia, according to regulatory labeling.

Mechanism of Action

How Biscor Works: Mechanism of Action

Biscor (Bisoprolol Fumarate) exerts its effect by acting as a selective competitive antagonist of the beta1-adrenergic receptors (beta1-AR) found predominantly on the heart and in the kidneys. Its mechanism operates by reducing the flow of excitatory signals from the sympathetic nervous system and modulating a key hormonal pathway.

Targeted Blockade of Cardiac Excitation

This interaction involves Biscor blocking beta1-AR on the heart's muscle and conduction system, preventing activation by Norepinephrine and Epinephrine. This molecular action initiates a cascade that results in a reduction in the heart rate (negative chronotropy) and a lessening of the force of contraction (negative inotropy).

Modulation via the Renal Renin-Angiotensin System

Simultaneously, the mechanism involves blocking beta1-AR on specialized juxtaglomerular cells in the kidney, which are responsible for releasing Renin. By inhibiting this release, Biscor indirectly modulates the Renin-Angiotensin System (RAS). This action alters humoral signals that affect vascular tone, resulting in the long-term modulation of systemic vascular resistance.

Dosage and Administration Information

How to Use Biscor

Biscor (Bisoprolol Fumarate) is a prescription-only medication administered exclusively via the oral route as a film-coated tablet. The tablets must be swallowed whole with water, preferably in the morning, and should not be crushed or chewed. The medication can be taken with or without food and should be administered at the same time each day for consistency.


Official Dosing and Administration Schedule

Biscor is generally used as a once-daily treatment for the long-term management of chronic cardiovascular conditions. The dosage depends significantly on the specific condition being addressed:

  • Hypertension and Angina Pectoris: Treatment typically begins with a dose of 5 mg once daily, though some patients may start at 2.5 mg. The dose may be adjusted up to a maximum recommended dose of 20 mg once daily.
  • Stable Chronic Heart Failure: Use in this context requires gradual up-titration starting with a low dose of 1.25 mg once daily. The dose is slowly increased in defined steps over several weeks up to a target maximum of 10 mg once daily, provided the patient tolerates the lower doses.

Procedural Constraints

Official labeling mandates specific procedural constraints to ensure proper use. The drug must not be stopped abruptly. Should discontinuation be necessary, the dosage must be slowly diminished (tapered) over a period of approximately one week. For patients with severe renal or hepatic impairment, the maximum daily dose is typically limited to 10 mg once daily. Use in the pediatric population is generally not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biscor

This section provides an overview of the research that has been conducted on Biscor (Bisoprolol Fumarate) across its main therapeutic areas. The following information describes what kinds of studies exist, what those studies examined, and what aspects of the treatment are still being researched or remain uncertain. This is a descriptive summary of the evidence and is not clinical advice.


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research includes multiple Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored patient populations and primarily examined outcomes related to the measurement of blood pressure, specifically changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), and changes in the patient's heart rate. The data described patterns observed in the studies related to the measurement of blood pressure in participants compared to the control groups.


Evidence for Use in Stable Chronic Heart Failure

Research for stable chronic heart failure (HFrEF) is based on large-scale Randomized Controlled Trials (RCTs), where studies explored outcomes related to measurements of long-term patient status, the frequency of being admitted to the hospital for worsening heart failure, and functional measures. The research describes changes measured during the study period in major outcomes like all-cause status and cardiovascular-related hospitalizations. Evidence is limited for patients with heart failure where the pumping function appears preserved (HFpEF).


Evidence for Use in Chronic Stable Angina Pectoris (Chest Pain)

Biscor was evaluated in studies for patients experiencing chronic stable angina, a condition characterized by fluctuating or episodic manifestations. Research examined outcomes related to physical discomfort, such as the frequency of anginal episodes, and tracked physical performance using exercise tolerance tests. The findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort. For this condition, follow-up durations were limited in many symptom-focused studies.


What is Still Uncertain About Biscor Research

Despite the established research base, certain aspects remain uncertain. The follow-up durations were limited in many studies focusing on short-term symptom exploration for angina and primary hypertension. Furthermore, data for certain groups remain insufficient, especially for populations outside the primary adult study cohorts (e.g., in children or pregnant women), so results apply only to the populations studied.

Key Studies & References

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (Major trial in Heart Failure)
  2. Hypertension (Guidelines) - NHS Scotland (Clinical guidance context for measurement and targets)

Frequently Asked Questions (FAQ)

Common questions about Biscor (FAQ)

Q: What is Biscor used for, exactly?

According to the official product information, Biscor (Bisoprolol Fumarate) is indicated for the management of high blood pressure (hypertension), chronic stable angina pectoris (chest pain), and stable chronic heart failure. This means studies have examined its use in patients with these specific cardiovascular conditions.


Q: Is Biscor the same type of drug as other 'beta blockers'?

Yes, Biscor belongs to the class of medicines known as beta-adrenergic receptor blocking agents. This class is commonly referred to as beta-blockers. Official documents describe Biscor’s mechanism as a selective competitive antagonist of the beta1-adrenergic receptors.


Q: How quickly does Biscor start working?

The initial effects of the medication on reducing heart rate and blood pressure begin within the first few hours of taking a dose. This is consistent with its peak plasma concentrations occurring within 2 to 4 hours. However, the full, steady-state effect of the medication is usually reached after about five days of once-daily dosing.


Q: What happens if I miss a dose of Biscor?

Regulatory patient information describes taking the missed dose as soon as it is remembered on that day. The guidance indicates that if it is almost time for the next dose, the missed dose is typically skipped, and the patient resumes the regular schedule. Official guidance cautions against taking a double dose to compensate for a forgotten one.


Q: Is it possible to take too much Biscor?

Yes, taking more than the prescribed amount is possible, and the guidance emphasizes the need for immediate medical attention if an overdose is suspected. Overdose may cause symptoms such as a dangerously slow heart rate, breathing difficulty, dizziness, or shaking.


Q: Are there any major diet restrictions while taking Biscor?

Official regulatory documents generally state that patients can continue their normal diet unless their prescribing doctor advises otherwise. There is no official classification of major dietary restrictions, although some guidance suggests limiting large amounts of caffeine.


Q: Does Biscor cause weight gain?

Unusual weight gain and peripheral edema (swelling due to fluid retention) are listed in some official product information. If a patient experiences unusual or rapid weight gain, regulatory safety information suggests that a healthcare professional should be consulted.


Q: What should I do if a side effect seems mild?

For common, mild side effects, such as headache or dizziness, some official guidance mentions that they may be alleviated by rest and adequate fluid intake. If any symptoms persist, worsen, or cause concern, official guidance recommends consultation with a doctor or pharmacist for further clarification.


Q: Is Biscor safe for people over 65?

In general, a dose adjustment is not required for elderly patients. Official guidance states that treatment should start with the lowest possible dose, and extra care is advised for those patients who are over the age of 80.


Q: Can Biscor affect my ability to drive or operate machinery?

The medication may cause common side effects such as tiredness, dizziness, or drowsiness. Regulatory documents state that when these effects are experienced, driving, cycling, or operating machinery should be avoided.


Q: Is Biscor safe for people with asthma?

Official product information states that Biscor is contraindicated, meaning its use is prohibited, in patients with severe bronchial asthma or severe chronic lung disease. In patients with milder asthma, the medicine must be used with caution and under close medical supervision.


Q: Can Biscor cause problems with circulation in the hands and feet?

Beta-blockade, the effect of this class of medicine, may impair peripheral circulation. This action could potentially worsen the symptoms of pre-existing peripheral vascular disease, which may be experienced as coldness or numbness in the hands and feet.


Q: Can women who are pregnant or breastfeeding use Biscor?

The medication is not generally recommended for use during pregnancy or while breastfeeding. Official documents indicate there may be a risk of harm to the unborn child or infant, including concerns such as low blood sugar or a reduced heart rate.


Q: Is it possible to be allergic to Biscor?

Yes, Biscor is contraindicated if a patient has a known hypersensitivity, or allergy, to the active drug or any of its components. Patient information sheets include descriptions of the symptoms that characterize a serious allergic reaction.


Q: Does Biscor interact with herbal remedies like St. John's wort?

Yes, St. John’s wort is specifically listed in regulatory documents as a supplement that may interfere with the effectiveness of Bisoprolol Fumarate. Official guidance advises patients to review the use of all herbal remedies and supplements with a healthcare professional.


Q: Does Biscor interact with any common supplements like multivitamins?

Regulatory information advises caution with certain supplements, noting that some, like St. John's wort or ginseng, may interfere with the medicine's effectiveness. It is generally recommended that patients review all supplements, including multivitamins, with a healthcare professional.


Q: Can Biscor interfere with birth control pills?

Official drug interaction information does not typically list direct interference with hormonal birth control. However, if gastrointestinal side effects such as vomiting or severe diarrhea occur, regulatory patient information notes that this could potentially reduce the absorption and effectiveness of oral contraceptives.


Q: Can Biscor be taken with antibiotics?

Regulatory information states a specific interaction with the antibiotic Rifampicin, which increases the metabolic clearance of the drug. It is recommended that the combination of Biscor with any antibiotic be reviewed with a healthcare professional.


Q: Can Biscor cause low blood sugar?

Official product information states that the medication can increase the blood sugar-lowering effect of insulin and other antidiabetic medicines. Furthermore, in patients with diabetes, it may mask the typical symptoms of low blood sugar, which is known as hypoglycemia.


Q: Are there different strengths of Biscor tablets available?

Yes, Bisoprolol Fumarate is described as being available in multiple film-coated tablet strengths. These include 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg tablets.


Q: What is the approved eligibility criteria for using Biscor?

Approved use depends on the specific, authorized condition being treated, such as high blood pressure, angina, or stable chronic heart failure. Eligibility requires that the patient does not have any of the specified contraindications, such as severe heart failure, severe bradycardia, or severe asthma.


Q: Does Biscor interact with cold and flu medications?

Official regulatory information indicates that Biscor interacts with certain cold and flu medications. Specifically, those containing ingredients like pseudoephedrine or xylometazoline may affect blood pressure or the medicine's effectiveness.

How should Biscor be stored and disposed of?

Storage Conditions

Biscor (Bisoprolol Fumarate) must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C. Brief temperature excursions between 15 C and 30 C are permitted. The tablets must be kept in their original container, tightly closed, and must be protected from both light and moisture to maintain product stability.

Child Safety and Disposal

It is a mandatory requirement to keep this medicine out of the reach and sight of children. For disposal, unused or expired tablets must be discarded in accordance with local regulations. Official guidance requires utilizing a drug take-back program if available. If not, follow the instructed household disposal method of mixing the product with an undesirable substance before discarding in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biscor found in:

A-Z Index: